Standards of Care Shift Toward Patient Specificities in Bladder and Prostate Cancers
October 13th 2022Shilpa Gupta, MD, discussed potential therapies for patients with cisplatin-ineligible metastatic urothelial carcinoma, the benefits of sacituzumab govitecan and erdafitinib in later-line urothelial carcinoma, and treatment options for nonmetastatic castration-resistant prostate cancer.
Read More
Increasingly Sensitive Genetic Testing Advances GI Cancer Diagnosis and Management
October 8th 2022John Lindsay Marshall, MD, discusses past, present, and future developments in molecular testing, as well as the unique offerings of tissue and blood tests and the ways in which these precise approaches will ultimately make cancer diagnosis and treatment more efficient and effective.
Read More
Efforts Underway to Generate Real-World Evidence for Second-line Strategies in SCLC
October 7th 2022Nicolas Girard, MD, PhD, highlights current treatment practices, the value real-world data would provide for future investigative approaches in SCLC, and the observed benefit of administering available treatment options such as lurbinectedin as early as possible.
Read More
Ivosidenib/Venetoclax/Azacitidine Proves Tolerable, Strengthens Survival in AML
October 6th 2022Ivosidenib plus venetoclax with or without azacitidine showed an expected and tolerable safety profile with durable responses and a prolonged survival rate across acute myeloid leukemia disease groups.
Read More
ASTX727/Venetoclax Combo Is Safe and Effective in First-Line and Relapsed/Refractory AML
October 5th 2022Oral decitabine plus cedazuridine added to oral venetoclax demonstrated promising overall response rates in patients with acute myeloid leukemia who received the combination as a first-line treatment or after relapsing on prior therapies.
Read More
Zanubrutinib Provides ORR, PFS Benefits Over Ibrutinib in Relapsed/Refractory CLL/SLL
October 4th 2022Zanubrutinib elicited significantly higher response rates and survival benefits compared with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma .
Read More
E-Selectin Upregulation and Chemo Combinations Among Recent Developments in AML
September 29th 2022E-selectin has emerged as a viable target in acute myeloid leukemia, and agents like uproleselan have the potential the increase AML cells’ sensitivity to chemotherapies such as cladribine plus low-dose cytarabine.
Read More
Frontline Aumolertinib Significantly Improves PFS Over Gefitinib in EGFR-Mutated NSCLC
September 29th 2022Aumolertinib significantly prolonged progression-free survival vs gefitinib in treatment-naïve patients with locally advanced or metastatic non–small cell lung cancer harboring EGFR mutations, according to findings from the phase 3 ANEAS trial published in the Journal of Clinical Oncology.
Read More
Pedmark Reduces Ototoxicity Risk in Cisplatin-Treated Pediatric Solid Tumors
September 29th 2022Nilay Shah, MD, discusses the importance of the FDA approval of sodium thiosulfate for pediatric patients with solid tumors, the favorable toxicity profile of the agent, and how clinical trial findings may inform future care in this population.
Read More
Tepotinib/Osimertinib Combo Induces ORR Benefit in EGFR-mutated NSCLC
September 27th 2022Julien Maziéres, MD, PhD, explains the importance of defining a second-line standard of care in the EGFR-mutated non–small cell lung cancer population, highlights the long-term benefits seen with tepotinib plus osimertinib, and previews the next steps that should be taken toward more individualized patient care.
Read More
Immunotherapy and Targeted Therapy Approaches Drive Advances in Biliary Tract Cancer
September 26th 2022Flavio G. Rocha, MD, FACS, FSSO, discusses the types of biliary tract cancer and what has been learned about them, explains the effects of systemic therapy on surgery, and relays remaining questions pertaining to the efficacy of immunotherapy.
Read More
Rusfertide May Eliminate Need for Frequent Phlebotomies in Polycythemia Vera
September 21st 2022Srdan Verstovsek, MD, PhD, discusses the benefits of rusfertide, an agent currently under evaluation in patients with polycythemia vera. In addition, he lays out the distinctions between low-risk and high-risk polycythemia vera and explains the benefits of this drug in both populations.
Read More
Enzalutamide Plus ADT Improves rPFS, OS in Metastatic HSPC With Prior ADT
September 20th 2022Enzalutamide plus androgen deprivation therapy elicited significant improvements in radiographic progression-free survival and overall survival vs placebo in patients with metastatic hormone-sensitive prostate cancer.
Read More
Durvalumab/Chemo Triplet Signifies Novel Advances in Treatment of Biliary Tract Cancer
September 15th 2022Mark Yarchoan, MD, lays out the evolution of drug development in biliary tract cancer, discusses the findings from the TOPAZ-1 trial, and shares the positive future direction of immunotherapy in this disease.
Read More
Late Effects Arise Irrespective of High-Dose Chemotherapy and ASCT Status in MCL
September 13th 2022Intensive first-line treatment with high-dose chemotherapy and autologous stem cell transplant was not associated with higher rates of late effects compared with outcomes from less intensive therapies in patients with mantle cell lymphoma.
Read More
Ribociclib plus endocrine therapy elicited statistically significant progression-free survival and overall survival benefits vs placebo plus endocrine therapy in patients with hormone receptor–positive/HER2-negative advanced breast cancer with visceral metastases, including those with liver metastases and multiple metastatic sites.
Read More
Magrolimab Plus Azacitidine May Be a Potential Treatment Option in High-Risk MDS
September 7th 2022Naval G. Daver, MD, discusses the rationale for the ongoing ENHANCE trial and explained magrolimab’s unique role as a macrophage immune checkpoint blocker. He also outlines unmet needs throughout the entire high-risk myelodysplastic syndrome population, and how novel approaches, such as magrolimab combinations, may fulfill these needs.
Read More
Immunotherapy in the form of ipilimumab plus nivolumab followed by the targeted therapy combination encorafenib plus binimetinib elicited an overall survival benefit in patients with untreated BRAF-mutated metastatic melanoma, according to findings from the phase 2 SECOMBIT trial.
Read More
Sacituzumab Govitecan Provides PFS Benefit Vs Chemotherapy in HR+/HER2– Breast Cancer
September 2nd 2022Sacituzumab govitecan displayed encouraging progression-free survival rates compared with single-agent chemotherapy in patients with locally recurrent inoperable or metastatic hormone receptor–positive, HER2-negative breast cancer, according to findings from the phase 3 TROPiCS-02 study.
Read More
Erlotinib Displays Long-Term DFS Benefit, Meaningful OS Improvement vs Chemotherapy in EGFR+ NSCLC
September 1st 2022Erlotinib continued to elicit a disease-free survival and overall survival benefit vs vinorelbine/cisplatin chemotherapy in patients with EGFR-positive non–small cell lung cancer, according to updated OS data and an exploratory analysis from the phase 2 EVAN trial.
Read More
Daratumumab-Containing Regimens Display PFS Benefit Across Myeloma Subgroups
September 1st 2022Daratumumab combinations elicited significant progression-free survival, overall survival, overall response rate, and minimal residual disease–negativity benefits vs control in pretreated patients with relapsed or refractory multiple myeloma across clinically relevant subgroups.
Read More
Multidisciplinary Management Stands at the Forefront of Breast Cancer Treatment
August 29th 2022Judy C. Boughey, MD, shares criteria for omission of sentinel lymph node surgery, the importance of not altering treatment based on identification of variants of uncertain significance, and the potential value of trastuzumab deruxtecan in HER2-low metastatic breast cancer.
Read More
Emerging Data are Expanding Treatment Options, Extending Survival Across Breast Cancer Subtypes
August 29th 2022Matthew P. Goetz, MD, discusses overall survival data with ribociclib and abemaciclib in estrogen receptor–positive, HER2-negative disease; the role of adjuvant pembrolizumab in patients with triple-negative breast cancer; and the efficacy of PARP inhibitors in earlier settings.
Read More